Although Johnson & Johnson is strong and also an industry leader, it has taken a very different path from Pfizer.

What is Johnson & Johnson's philosophy?

Decentralization = Creativity = Productivity!

Johnson & Johnson Group made a fortune in making sterile dressings, but the truly world-renowned product is not sterile dressings, it may just be a "band-aid" created by one of his employees cutting his finger while cooking, or it may be Johnson & Johnson diapers and so on......

Johnson & Johnson has always believed that small, fully licensed companies can create new products and develop new markets, so it has tried to keep its own small and independent company, responsible for production, marketing, distribution and research and development, and maintain independence after the acquisition of new companies, and continue to spin off from existing organizations into independent companies.

Today, Johnson & Johnson has 150 companies, of which more than 20 are major companies, and the rest are newly acquired companies or spun off from these 20 or more.

Each company is independent and 100 percent owned by Johnson & Johnson. Under the philosophy of decentralization and innovation, Johnson & Johnson has quadrupled in 10 years from 1972 to 1982, with sales of $3.3 billion in 1982, 79,000 employees worldwide, and an annual return on equity of nearly 20%.

However, Johnson & Johnson and China have long been cooperating, and in 1985, Johnson & Johnson established its first joint venture in China, Xi'an Janssen Pharmaceutical Co., Ltd. Subsequently, Shanghai Johnson & Johnson Co., Ltd., Johnson & Johnson (China) Co., Ltd., Johnson & Johnson (China) Medical Device Co., Ltd. and Shanghai Johnson & Johnson Pharmaceutical Co., Ltd. were established successively.

Today, Johnson & Johnson has more than 6,000 employees in China and manufactures a wide range of products, including consumer and personal care products, pharmaceutical products, and medical devices and diagnostics.

However, Johnson & Johnson's core competitiveness is not within these branches, these companies are just a commodity economy similar to the nature of enterprises.

Johnson & Johnson has begun to change over the years and began to emphasize the core, because the expansion of external products is only a value-added business, not a core competitiveness.

Just like the development of Xiaomi Group, for a period of time, it can rely on the diversification of products to continuously expand the market, but if it lacks a core competitiveness, Xiaomi's future is limited.

At this point, Bai Ye had already had further communication with Mr. Lei, and the other party had already begun to prepare.

As a large international enterprise, how can Johnson & Johnson not understand this?

Therefore, Bai Ye is looking for Johnson & Johnson Group this time, hoping to communicate with Johnson & Johnson and strengthen each other.

In fact, compared with Pfizer, Bai Ye attaches more importance to Johnson & Johnson in some places, that is, the field of cooperation with Johnson & Johnson Group, this guy is too big, just like a behemoth, and its subsidiaries are basically involved in health-related peripheral industries.

Therefore, the cooperation with Johnson & Johnson can not only drive the development of medicine, but also the development of the entire economy.

China's manufacturing industry is still well-known in the world, for example, the ten-year lawsuit between Johnson & Johnson and China Guilin Zhonghui Company over blood glucose test strips can be seen that the people of the Chinese nation have never lacked creativity and productivity.

Moreover, Bai Ye's current development model of the Checks and Balances Group is very similar to the current Johnson & Johnson Group!

It's just that the marketing model is different.

The product coverage rate of the Balance Group is very high, and Bai Ye has basically contracted the lottery over the years, but the reputation of the Balance Group is not as good as Johnson & Johnson, which limits his market.

Bai Ye felt that the Checks and Balances Group needed to be listed, and it was entirely possible to take advantage of the turmoil in the listing of the Puxikang drug this time to make the Checks and Balances Group go public smoothly.

His cooperation with Johnson & Johnson is in the field of medical devices.

Bai Ye also has a valuable opportunity to designate upgrade items, and he can take advantage of this opportunity to enter the medical testing market with the help of the platform of Johnson & Johnson Group.

This market is a short board in China!

For a long time, Bai Ye did not want to enter quickly, because medical treatment, such as physiological and biochemical tests, such as complex large-scale CT machines, nuclear magnetic resonance, etc., requires definitely not only the medical field, but also involves cooperation in many fields such as physics and chemistry.

So, it's definitely not as simple as you think.

What Bai Ye wants to take advantage of now is that strengthening opportunity, hoping to cooperate with Johnson & Johnson Group to go further in the development of medical testing equipment.

In fact, SPOM is the most suitable group in this field, but the only thing that does not cooperate is that SPOM has dealt with Bai Ye several times, and found that this company's attitude towards China makes Bai Ye very uncomfortable.

Therefore, Bai Ye found Johnson & Johnson.

If Johnson & Johnson's core technology can remain in China and benefit China, this contribution will be great.

This time, Johnson & Johnson did not meet with Johnson & Johnson in China, but Mr. Heath, the chief engineer of Johnson & Johnson's headquarters in the United States.

After Hiss saw Bai Ye, he smiled: "Professor Bai Ye, young and promising. ”

Bai Ye smiled, shook his head and said, "Compared with Mr. Heath, there is still a little gap, I met today to talk to you about our cooperation." ”

Hiss's eyes lit up: "Are you willing to hand over Puxikang to us?" Professor Bai Ye, if this is the case, you will definitely not regret what you did today, I believe that our Johnson & Johnson Group can definitely afford to give a satisfactory number!"

Bai Ye shook his head: "No, no, no, it's not Puxikang." It's a different kind of item. ”

When Hiss heard this, he smiled: "Oh, hehe, is it about the research progress of your research team on tumor cells in this study? Maybe this news surprises me even more!"

Bai Ye continued to shake his head: "No, my cooperation with Johnson & Johnson Group is not the research of tumors, nor is it the development of new drugs, because what your company is good at is not the development of new drugs." To be honest, I don't think it's a good choice to work with your company on oncology, and Pfizer has gone far further in oncology research and development. ”

"And, to be honest with Mr. Heath, I have already had some communication with the management of Pfizer, and I hope to conduct in-depth research and cooperation with Pfizer Group, and we are willing to work together in the research and development of tumors. ”

When Hiss heard this, his face suddenly changed!

That's not good news!

Pfizer and Johnson & Johnson have always been competitors, and although there is no precise fight for a certain product, there have always been minor frictions.

Even in order to prevent the other party from becoming the industry leader, he stumbled the other party.

If......

Hiss didn't dare to think about it anymore, he thought of this possibility, and he was a little ...... Afraid?